Artelo Biosciences (ARTL) News Today $2.33 +0.13 (+5.91%) Closing price 10/28/2026 04:00 PM EasternExtended Trading$2.36 +0.02 (+1.07%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsSEC Filings Artelo Biosciences Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Artelo Biosciences to Present ART26.12 Data at IASP World Congress on Pain as First Selective FABP5 Inhibitor Advances Toward MAD StudyOctober 26 at 8:11 AM | quiverquant.comQArtelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on PainOctober 26 at 7:55 AM | globenewswire.comArtelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-EuropeOctober 7, 2026 | rttnews.comArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformOctober 7, 2026 | globenewswire.comArtelo Biosciences (ARTL)September 23, 2026 | es.investing.comArtelo Expands ART27.13 Patent Coverage After Obesity Study FindingsSeptember 23, 2026 | rttnews.comArtelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?September 23, 2026 | benzinga.comArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected ...September 23, 2026 | finance.yahoo.comArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical FindingsSeptember 23, 2026 | globenewswire.comArtelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity ModelSeptember 16, 2026 | rttnews.comArtelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical ...September 16, 2026 | tmcnet.comArtelo Biosciences Reports ART27.13 Produced Semaglutide-Like Weight Loss in Obese Mice and Doubled Results in Combination StudySeptember 16, 2026 | quiverquant.comQArtelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of ObesitySeptember 16, 2026 | globenewswire.comArtelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | finance.yahoo.comArtelo Biosciences Announces Reverse Stock SplitAugust 27, 2026 | globenewswire.comArtelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13August 20, 2026 | globenewswire.comArtelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 StudiesAugust 17, 2026 | globenewswire.comArtelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial ResultsAugust 13, 2026 | globenewswire.comArtelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of GlaucomaAugust 10, 2026 | markets.businessinsider.comArtelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with NaproxenJuly 16, 2026 | quiverquant.comQArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain ConditionsJuly 16, 2026 | globenewswire.comArtelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026July 14, 2026 | globenewswire.comArtelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer PatientsJuly 13, 2026 | quiverquant.comQArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral NeuropathyJuly 13, 2026 | globenewswire.comArtelo Biosciences Adjourns and Reschedules 2025 Annual MeetingJuly 10, 2026 | theglobeandmail.comArtelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord InjuryJuly 1, 2026 | globenewswire.comArtelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 InhibitionJune 30, 2026 | quiverquant.comQArtelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026June 30, 2026 | globenewswire.comArtelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker ResearchJune 29, 2026 | quiverquant.comQArtelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026June 29, 2026 | globenewswire.comArtelo Biosciences Presents Promising Metabolite Profiling Data for Lead FABP Inhibitor ART26.12 at Medicinal Chemistry ConferenceJune 10, 2026 | quiverquant.comQArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development SuccessJune 10, 2026 | globenewswire.comArtelo Biosciences Launches Flexible At-The-Market OfferingMay 27, 2026 | tipranks.comArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial ResultsMay 14, 2026 | markets.businessinsider.comArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 ...April 28, 2026 | markets.businessinsider.comArtelo Biosciences Partners with ScienceMachine to Enhance FABP5 Inhibitor Development Through AI TechnologyApril 28, 2026 | quiverquant.comQArtelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor DevelopmentApril 28, 2026 | globenewswire.comWhat's behind the rise in Artelo Biosciences stock?April 21, 2026 | msn.comWhat's Behind The Rise In Artelo Biosciences Stock?April 20, 2026 | benzinga.comArtelo Biosciences jumps after Nasdaq compliance update, with low-float volatility likely adding fuelApril 20, 2026 | quiverquant.comQArtelo Biosciences Highlights Promising Efficacy and Safety Profile of ART26.12 as a Novel Pain Treatment Ahead of Upcoming Clinical StudiesApril 20, 2026 | quiverquant.comQArtelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class ProfileApril 20, 2026 | globenewswire.comArtelo Biosciences Regains Compliance with Nasdaq Listing RulesApril 7, 2026 | quiverquant.comQArtelo Biosciences Regains Compliance with Nasdaq Listing RequirementsApril 7, 2026 | globenewswire.comArtelo Biosciences, Inc. Completes $11 Million Private Placement of Common Stock and WarrantsMarch 30, 2026 | quiverquant.comQArtelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesMarch 30, 2026 | globenewswire.comArtelo Biosciences IncMarch 27, 2026 | cnn.comWhy did ARTL stock skyrocket over 141% pre-market today?March 27, 2026 | msn.comArtelo Biosciences shares surge as company pitches GLP-1 companion-therapy angle for ART27.13March 27, 2026 | quiverquant.comQArtelo Biosciences, Inc. Announces Private Placement of Common Stock and Warrants, Expected Proceeds of $11 MillionMarch 27, 2026 | quiverquant.comQ Artelo Biosciences Media Mentions By Week Artelo Biosciences Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTL News Sentiment▼1.210.68▲Average Healthcare News Sentiment Artelo Biosciences News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTL Articles This Week▼33▲ARTL Articles Average Week Artelo Biosciences Trends on MarketBeatThis week vs. last weekSearches3+200%Page Views1,325-6% Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Traws Pharma News Lexaria Bioscience News Moleculin Biotech News Sonoma Pharmaceuticals News Pulmatrix News Heatwurx News Scienture News Gelteq News InMed Pharmaceuticals News Redhill Biopharma News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Artelo Biosciences dated 10/26/2026. From Our PartnersThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
